Thursday, February 18th, 2021

Thursday Feb 18th MORNING SESSION
8:00 AM – 11:30 AM (PT)

8:00 – 8:15 AM (PT)
CONNECTIVITY (TEST SYSTEM) AND MEETING OPENING AND INTRODUCTIONS

Norman Lacayo, MD
Director, POETIC

8:15 – 9:00 AM (PT)
THE RACE FOR CHILDREN ACT: CHANGING THE LANDSCAPE FOR PEDIATRIC CANCER DRUG DEVELOPMENT

Keynote speaker Gregory Reaman, MD
Associate Director, Office of Hematology and Oncology Products, CEDER, U.S. FDA

9:00 – 9:45 AM (PT)
DRUG DEVELOPMENT: A EUROPEAN PERSPECTIVE

Michel Zwaan, MD
Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands

9:45-10:30 AM (PT)
THE DRUG REDISCOVERY PROTOCOL: EXPANDED USE OF EXISTING ANTICANCER DRUGS

Laurien J. Zeverijn, MD
Department of Molecular Oncology and Immunology, Laboratory of Emile Voest
Netherlands Cancer Institute, Amsterdam

10:30-11:30 AM (PT)
60 MIN LUNCH BREAK
**Thursday Feb 18th, AFTERNOON SESSION**  
**11:30 AM – 3:00 PM (PDT)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 11:30 – 11:45 AM (PT) | **GHANA PROJECT**  
   *Tanya Trippett, MD*  
   Co-Founder and Director Emeritus, POETIC  
   Pediatric Hematologic Malignancies, Memorial Sloan Kettering Cancer Center |                                                                                                 |
| 11:45 AM – 12:00 PM (PT) | **POETIC UPDATES: POE16-01 STUDY**  
   *Tanya Trippett, MD*  
   Co-Founder and Director Emeritus, POETIC  
   Pediatric Hematologic Malignancies, Memorial Sloan Kettering Cancer Center |                                                                                                 |
| 12:00 – 12:15 PM (PT)  | **POETIC UPDATES: POE14-01 STUDY**  
   *Jessica Boklan, MD*  
   Director, Clinical Oncology Research; Director, Early Drug Development Program; Co-Director, Leukemia, Lymphoma, Histiocytosis Program, Phoenix Children’s Hospital | **Aru Narendran, MD, PhD, FAAP**  
   Professor of Oncology and Pediatrics, Alberta Children’s Hospital |
| 12:15 – 12:45 PM (PT) | **GENENTECH PEDIATRIC CLINICAL DEVELOPMENT UPDATE**  
   *Ronald Bernardi, MD, PhD*  
   Associate Medical Director, innovative Pediatric Oncology Drug Development (iPODD), Product Development Oncology (PDO) Roche/Genentech |                                                                                                 |
| 12:45 – 1:15 PM (PT) | **PARPAML: A PHASE 1 PROTOCOL FOR RELAPSED PEDIATRIC AML TO DETERMINE THE SAFETY AND EFFICACY OF THE PARP INHIBITOR TALAZOPARIB IN COMBINATION WITH CONVENTIONAL CHEMOTHERAPY**  
   *Jennifer Kamens, MD*  
   Instructor, Stanford University and Lucile Packard Children’s Hospital, Pediatrics Hematology Oncology, Stanford |                                                                                                 |
| 1:15 - 1:30 PM (PT) | **15 MIN BREAK (+KUDOS CORNER)**                                                                 |                                                                                                 |
| 1:30 – 2:00 PM (PT) | **NOVEL THERAPEUTIC AGENTS FOR NEXT GENERATION POETIC CLINICAL TRIALS**  
   *Aru Narendran, MD, PhD, FAAP*  
   Professor of Oncology and Pediatrics, Alberta Children’s Hospital |                                                                                                 |
| 2:00 – 2:30 PM (PT) | **EXOSOME BIOMARKERS FOR EARLY CANCER DETECTION IN ADULT AND PEDIATRIC CANCERS**  
   *David Lyden, MD, PhD*  
   Professor of Pediatrics and Cell and Developmental Biology, Cornell University |                                                                                                 |
| 2:30 – 3:00 PM (PT) | **EXPANDED ACCESS: WHAT IS IT AND HOW CAN IT HELP PEDIATRIC CANCER PATIENTS AND RESEARCHERS?**  
   *Mark Shapiro, MBA, MA*  
   VP Clinical Development, xCures |                                                                                                 |
| 3:00 – 3:30 PM (PT) | **THE ZERO PROGRAM**  
   *Glenn Marshall, AM, MB, BS, MD, FRACP, FAHMS*  
   Pediatric Hem-Onco, Kids Cancer Centre, Sydney Children’s Hospital, Australia |                                                                                                 |

**MEETING ADJOURNED**
Friday, February 19th, 2021

Friday February 19th MORNING SESSION
8:00 AM – 11:30 AM (PT)

8:00 – 8:10 AM (PT)
CONNECTIVITY (TEST SYSTEM) GREETINGS/INTRODUCTIONS
Norman Lacayo, MD
Director, POETIC

8:10 – 9:00 AM (PT)
COMPASSIONATE USE FOR PEDIATRIC PATIENTS: ETHICS, REGULATION, AND OVERSIGHT
Alison Bateman-House, MPH, PhD, MA
Assistant Professor, Division of Medical Ethics, NYU Grossman School of Medicine

9:00 – 9:30 AM (PT)
PATIENT ADVOCATE TALK - EXPANDED ACCESS OF ONC201 FOR DIFFUSE MIDLINE GLIOMA (DMG)
Anne Donguy
Patient advocate-Parent

9:30 – 10:00 AM (PT)
SURVIVORSHIP AND SYMPTOM MANAGEMENT
Stephanie Smith
Instructor, Pediatrics Hematology Oncology, Stanford

10:00 – 10:30 AM (PT)
90 MIN LUNCH BREAK

10:30 – 11:30 AM (PT)
POETIC WORKING GROUPS BREAKOUT ROOMS (+LUNCH)

Friday February 19th AFTERNOON SESSION
11:30 AM – 3:00 PM (PT)

11:30 AM – 12:00 PM (PT)
CLINICAL ACTIVITY AND BIOMARKER ANALYSES OF ODRONEXTAMAB (REGN1979), A HUMAN CD20 x CD3 BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Srikanth Ambati, MBBS, MD
Senior Medical Director, Clinical Sciences Oncology and Hematology, Regeneron

12:00 – 12:30 PM (PT)
DEVELOPMENT OF APL-101, A HIGHLY SPECIFIC C-MET INHIBITOR, FOR LUNG AND BRAIN CANCERS
Sanjeev Redkar, PhD, MBA
President, Apollomics

12:30 – 1:00 PM (PT)
JOHNSON AND JOHNSON MENIN PROGRAM AND PEDIATRICS
Nikki Daskalakis, MD
Executive Director, Early Development Oncology, The Janssen Pharmaceutical Companies of J&J

1:00 – 1:15 PM (PT)
15 MIN BREAK

1:15 – 1:45 PM (PT)
BRAIN IMMUNOLOGY AND IMMUNOTHERAPY IN BRAIN TUMORS
David M. Ashley, MBBS (Hon), FRACP, PhD
Director, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University

2.5.2021
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
</table>
| 1:45 – 2:15 PM (PT) | TRANSFORMING THE WAY RESEARCHERS SHARE DATA – LESSONS FROM THE PEDIATRIC CANCER DATA COMMONS | **Samuel Volchenboum, MD, PhD**  
Dean of Master's Education  
Associate Professor of Pediatrics  
Director, Pediatric Cancer Data Commons  
Associate Director, Institute for Translational Medicine  
Associate Chief Research Informatics Officer |
| 2:15 – 2:45 PM (PT) | OVERVIEW OF THE BAYER ONCOLOGY PIPELINE: PEDIATRIC EDITION | **Flavia Menezes, MD**  
Senior Clinical Development Leader-Pediatric Oncology, Bayer  
**John Chung, MD**  
Pediatric Oncology Development Lead and Early Oncology Lead, Bayer |
| 3:30 – 5:00 PM (PT) | POETIC PI MEETING (Closed Session) | **Jonathan D. Schwartz, DO MSPH FAAP**  
Pediatric Neuro-Oncology  
Assistant Professor of Pediatrics  
Division of Pediatric Hematology/Oncology  
Department of Pediatric and Adolescent Medicine  
Mayo Clinic, Rochester |